Ocular Therapeutix, Inc. Wins FDA Panel Date for ReSure Sealant

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

An FDA advisory panel will review the ReSure sealant made by Ocular Therapeutix, a hydrogel designed to seal incisions in the eye’s cornea. An FDA advisory panel is slated to convene Sept. 19 to review the pre-market approval application for Ocular Therapeutix Inc.'s ReSure sealant. The FDA’s Ophthalmic Devices Panel will review the PMA for the ReSure product, a hydrogel designed to seal incisions to the cornea made during cataract or intraocular lens placement surgery.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC